文献速递肿瘤 PET/CT核素与放射性配体治疗

含Polatuzumab vedotin方案治疗的弥漫大B细胞淋巴瘤中[18F]FDG PET/CT对结局的预测价值

[18F]FDG PET/CT for outcome prediction in diffuse large B-cell lymphoma treated with polatuzumab vedotin-containing regimens.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-19

回顾性纳入39例接受含Polatuzumab vedotin方案并预处理前行[18F]FDG PET/CT的弥漫大B细胞淋巴瘤患者,中位随访17.2个月,16例(41.0%)进展。完全代谢缓解患者结局优于部分代谢缓解患者;首次随访PET的SUVmean(P=0.016,HR=1.27)和MTV(P=0.002,HR=1.01)为无进展生存的独立预测因素。

要点

  • 完全代谢缓解患者结局优于部分代谢缓解患者。
  • SUV 4.0分割法MTV和TLG预测性能优于41% SUVmax法。
  • 首次随访PET的SUVmean和MTV是无进展生存独立预测因素。

核心结论

  • 完全代谢缓解患者结局优于部分代谢缓解患者,首次随访PET的SUVmean和MTV是无进展生存的独立预测因素,提示[18F]FDG PET/CT可能在预测含Pola方案治疗的DLBCL患者结局中起重要作用。

研究设计与样本

  • 回顾性纳入39例接受含Polatuzumab vedotin方案并预处理前行[18F]FDG PET/CT的弥漫大B细胞淋巴瘤患者并进行随访。

主要发现

  • 中位随访17.2个月(范围3.28个月至26.2个月),期间16例(41.0%)进展。
  • 完全代谢缓解患者结局优于部分代谢缓解患者。
  • 基于SUV 4.0分割法的MTV和TLG预测性能优于基于41% SUVmax法。
  • 多因素Cox回归分析确定首次随访PET的SUVmean(P=0.016,HR=1.27)和MTV(P=0.002,HR=1.01)为无进展生存的独立预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the prognostic values of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) treated with Polatuzumab vedotin (Pola)-containing regimens. MATERIALS AND METHODS: Thirty-nine patients who received Pola-containing regimens and underwent pre-treatment [18F]FDG PET/CT were retrospectively enrolled and followed up. Qualitative response was assessed using Lugano criteria on follow up PET. Quantitative [18F]FDG PET parameters including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were evaluated using two segmentation methods (SUV 4.0 and 41% SUVmax), and changes in these indices (Δvalues) between pre-Pola and first follow-up PET scans were calculated. The prognostic values of PET metabolic parameters, clinical characteristics, and laboratory indicators were evaluated using time-dependent receiver operating characteristic (ROC) curve, and Cox regression analysis. Survival functions were estimated by Kaplan-Meier analysis. RESULTS: The median follow-up duration was 17.2 months (range 3.28 months - 26.2 months). During this period, 16 patients (41.0%) experienced progression. Patients with complete metabolic responses (CMR) exhibited superior outcomes than patients with partial metabolic responses (PMR). ROC and Cox analysis demonstrated that MTV and TLG based on SUV 4.0 segmentation showed superior predictive performance than those based on the 41% SUVmax method. Multivariate Cox regression analysis identified SUVmean (P = 0.016, HR = 1.27) and MTV (P = 0.002, HR = 1.01) on first follow-up PET as independent predictors of progression-free survival (PFS). CONCLUSION: CMR patients exhibited superior outcomes than PMR patients, and SUVmean and MTV on the first follow-up PET were independent predictors of PFS, suggesting that [18F]FDG PET/CT may play an important role in predicting outcomes of DLBCL patients treated with Pola-containing regimens.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yu C, Wang J, Chen L, et al. [18F]FDG PET/CT for outcome prediction in diffuse large B-cell lymphoma treated with polatuzumab vedotin-containing regimens. Eur J Nucl Med Mol Imaging. 2025. PMID: 40970963. doi:10.1007/s00259-025-07561-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。